Adaptive Biotechnologies reported a breakout 2025: total revenue rose 55% to $277 million, driven by 46% growth in its Minimal Residual Disease (MRD) business to $212 million and surging clonoSEQ test volumes. The MRD segment delivered positive adjusted EBITDA and cash flow, while companywide adjusted EBITDA turned positive at $12.2 million as net loss narrowed to $59.5 million. Operationally, the company secured expanded Medicare coverage for clonoSEQ in mantle cell lymphoma recurrence monitoring, integrated clonoSEQ into Flatiron Health’s OncoEMR to streamline community oncology ordering, implemented NovaSeq X Plus to scale sequencing, and recognized $19.5 million in MRD pharma regulatory milestone revenue. In parallel, Adaptive signed two non-exclusive immune receptor data licensing agreements with Pfizer. For 2026, the company guided MRD revenue to $255–$265 million and total operating expenses to $350–$360 million, while withholding guidance for the immune medicine segment.
The strategic signal is clear: MRD is becoming one of the rare diagnostics franchises to achieve scale economics, and Adaptive is concentrating execution on the part of its platform that pays today. Yet the sustainability test remains. A meaningful portion of 2025 performance reflected the full amortization of past Genentech payments within immune medicine; excluding this, total revenue grew 42% to $235.7 million and adjusted EBITDA remained a loss of $29.1 million. The path to companywide profitability will hinge on continued payer expansion, operational throughput gains, and whether immune receptor data can evolve from episodic deals into a recurring revenue engine.
For clinicians, embedding clonoSEQ ordering and results into OncoEMR removes workflow friction in community oncology where most patients are treated, a practical lever that often matters more than scientific persuasion. For patients, expanded Medicare coverage in mantle cell lymphoma normalizes MRD surveillance in another hematologic setting, supporting earlier intervention and therapy optimization. For payers, the combination of rising test volumes, regulatory milestone receipts, and scale on NovaSeq X Plus will intensify the demand for real-world evidence linking MRD-guided decisions to outcomes and cost offsets across lines of therapy. And for biopharma, non-exclusive licensing of Adaptive’s TCR–antigen maps and the accumulation of MRD-related regulatory milestones underscore how immune receptor data and standardized MRD endpoints are becoming embedded in trial design, registrational strategies, and label expansion plans.
The competitive landscape in MRD—spanning established liquid biopsy players and hematology-focused rivals—now faces a higher bar. Positive segment-level cash flow plus EMR channel integration is a combination that tends to accelerate share gains in community practices. At the same time, Adaptive’s financing mix, including a revenue interest liability, and its operating expense guidance imply continued investment to cement leadership while insulating unit economics. The absence of immune medicine guidance highlights ongoing lumpiness in data monetization and the need to broaden beyond one-off revenue recognition into contracts that refresh and scale.
The industry context is converging around three themes: diagnostics profit pools concentrating in high-utility surveillance tests; EMR-native commercialization as a prerequisite for community adoption; and the emergence of immune receptor atlases as strategic data assets for drug development. The next twelve months will test whether Adaptive can translate these advantages into durable, diversified earnings. Watch for further coverage expansions, deeper EMR integrations, conversion of data licensing into multi-year annuities, and evidence that MRD-driven decisions change outcomes at scale. The sharper strategic question: can Adaptive parlay its immune medicine platform into a repeatable, payer-accepted product suite beyond MRD, or will growth remain tethered to oncology testing economics as larger liquid biopsy competitors push into the same clinics?
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
